Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
OTC Markets OTCPK - Delayed Quote USD

Arch Therapeutics, Inc. (ARTH)

Compare
0.1790
+0.0169
+(10.43%)
At close: April 4 at 4:00:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Total Revenue
148.1630
75.7240
15.6520
11.5650
--
Cost of Revenue
89.5210
78.1630
51.4890
26.2820
--
Gross Profit
58.6420
-2.4390
-35.8370
-14.7170
--
Operating Expense
4,780.4490
5,042.0440
5,672.9690
6,362.4070
5,352.1140
Operating Income
-4,721.8070
-5,044.4830
-5,708.8060
-6,377.1240
-5,352.1140
Net Non Operating Interest Income Expense
-7,540.8610
-3,096.5500
-567.0480
-150.5310
-18.5340
Other Income Expense
--
1,158.1970
1,000
287.1730
679.2710
Pretax Income
-12,262.6680
-6,982.8360
-5,275.8540
-6,240.4820
-4,691.3770
Net Income Common Stockholders
-12,262.6680
-6,982.8360
-5,275.8540
-6,240.4820
-4,691.3770
Diluted NI Available to Com Stockholders
-12,262.6680
-6,982.8360
-5,275.8540
-6,240.4820
-4,691.3770
Basic EPS
-1.01
-2.27
-4.40
-6.00
-4.00
Diluted EPS
-1.01
-2.27
-4.40
-6.00
-4.00
Basic Average Shares
5,537.8080
3,074.1150
1,199.5750
1,100.0070
940.2580
Diluted Average Shares
5,537.8080
3,074.1150
1,199.5750
1,100.0070
940.2580
Total Operating Income as Reported
-4,721.8070
-5,044.4830
-5,708.8060
-6,377.1240
-5,352.1140
Total Expenses
4,869.9700
5,120.2070
5,724.4580
6,388.6890
5,352.1140
Net Income from Continuing & Discontinued Operation
-12,262.6680
-6,982.8360
-5,275.8540
-6,240.4820
-4,691.3770
Normalized Income
-12,262.6680
-8,141.0330
-6,275.8540
-6,527.6550
-5,370.6480
Interest Expense
3,579.5850
3,096.5500
567.0480
150.5310
18.5340
Net Interest Income
-7,540.8610
-3,096.5500
-567.0480
-150.5310
-18.5340
EBIT
-8,683.0830
-3,886.2860
-4,708.8060
-6,089.9510
-4,672.8430
EBITDA
-8,680.8480
-3,884.3200
-4,705.6100
-6,087.3640
-4,665.9170
Reconciled Cost of Revenue
89.5210
78.1630
51.4890
26.2820
--
Reconciled Depreciation
2.2350
1.9660
3.1960
2.5870
6.9260
Net Income from Continuing Operation Net Minority Interest
-12,262.6680
-6,982.8360
-5,275.8540
-6,240.4820
-4,691.3770
Total Unusual Items Excluding Goodwill
--
1,158.1970
1,000
287.1730
679.2710
Total Unusual Items
--
1,158.1970
1,000
287.1730
679.2710
Normalized EBITDA
-8,680.8480
-5,042.5170
-5,705.6100
-6,374.5370
-5,345.1880
9/30/2020 - 1/2/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NERV Minerva Neurosciences, Inc.
1.3700
-11.04%
 
MAZE Maze Therapeutics, Inc.
9.07
-2.68%
 
ZURA Zura Bio Limited
1.0300
-5.07%
 
RLFTF Relief Therapeutics Holding SA
2.2500
0.00%
 
GLYC GlycoMimetics, Inc.
0.1800
-2.76%
 
CVKD Cadrenal Therapeutics, Inc.
16.17
-5.66%
 
AVIR Atea Pharmaceuticals, Inc.
2.7900
-3.79%
 
EVFM Evofem Biosciences, Inc.
0.0100
+12.36%
 
IGC IGC Pharma, Inc.
0.2700
-3.30%
 
CLRB Cellectar Biosciences, Inc.
0.2644
-9.82%